Founded in 1986, IBA is a leader in the field of particle accelerator technology and has grown to become one of the world's largest companies providing services and equipment to businesses within the nuclear medicine and cancer therapy markets, as well as irradiation processing markets for the sterilization of healthcare products, microbial reduction for food safety, sanitization of mail, and the enhancement of industrial materials such as polymers, semiconductors and cable sheaths.
IBA products include dose verification equipment for radiation therapy and diagnostics, high-power electron accelerators, providing electron beam and X-ray radiation, as well as a wide range of advanced-technology cyclotron systems for radiotherapy and nuclear medicine. Our worldwide network of service centers includes facilities offering gamma, electron beam, X-ray, steam and ethylene oxide sterilization, laboratory testing and analytical services, and the production and distribution of radioisotopes for the diagnosis and treatment of select cancers.
IBA's global businesses operate within three primary business segments: Sterilization & Ionization; Radioisotope Production & Distribution; and Technology Services & Equipment. The company maintains international headquarters in Louvain-la-Neuve, Belgium is quoted on the pan-European stock exchange, EURONEXT, under the symbols IOBAt.BR (Reuters) and IBAB.BB (Bloomberg).